Aldeyra Therapeutics

Company snapshot

Aldeyra Therapeutics discovers and develops innovative therapies designed to treat immune-mediated diseases. Our approach is to develop therapies that modulate immunological systems, instead of inhibiting or activating single targets, with the goal of optimizing multiple pathways at once while minimizing toxicity. Two of our lead product candidates, reproxalap and ADX-629, target pre-cytokine, sys

• 2 approved product(s) across US/EU regulatory metadata.
• 26 active pipeline program(s) linked via ClinicalTrials.gov.
• 38 US patent(s) indexed to this assignee profile.

Public regulatory, clinical, patent, and corporate records for Aldeyra Therapeutics. Not investment advice.

• Peer + 0 momentum

  HRA Pharma

  TA overlap score 22.2

Recent activity

Latest pipeline, patent, and corporate events for Aldeyra Therapeutics.

1. Jun 8, 2026 Clinical update

   Reproxalap Ophthalmic Solution (0.25%) QID — Phase 3

2. Jun 8, 2026 Clinical update

   Reproxalap Ophthalmic Solution (0.25%) — Phase 2

3. Jun 8, 2026 Clinical update

   Reproxalap Ophthalmic Solution (0.25%) — Phase 2

4. Jun 8, 2026 Clinical update

   Reproxalap Ophthalmic Solution (0.25%) — Phase 3

5. Jun 8, 2026 Clinical update

   Reproxalap Ophthalmic Solution (0.25%) — Phase 3

View all clinical trial activity →

• What is Aldeyra Therapeutics?

  Aldeyra Therapeutics is a pharma organization headquartered in Lexington, USA. It trades on NYSE under ticker ALDX. Primary therapeutic focus areas include Dry Eye, Conjunctivitis, Allergic, Dry Eye Syndromes, Non-infectious Anterior Uveitis, Allergic Conjunctivitis. NovaPharmaNe

• Is Aldeyra Therapeutics publicly traded?

  Yes. Aldeyra Therapeutics is listed with ticker ALDX on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Aldeyra Therapeutics develop or market?

  We link 12 drug profile(s) where Aldeyra Therapeutics is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/aldeyra-therapeutics#company-drugs.

• What are the latest developments for Aldeyra Therapeutics?

  In the last 12 months our linked public records show 26 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Aldeyra Therapeutics focus on?

  Aldeyra Therapeutics focuses on Dry Eye, Conjunctivitis, Allergic, Dry Eye Syndromes based on our analysis of their pipeline programs and drug development activities.